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Multiple myeloma (MM) is a heterogeneous group of disorders both genotypically and phenoty-
pically. Response to thalidomide-based induction therapy in newly diagnosed patients varies
significantly in published clinical trials. Proteomic analysis was performed on 39 newly diagnosed
MM patients treated with a thalidomide-based regimen (22 responders; 17 non-responders) using
immunodepletion, 2-D DIGE analysis and mass spectrometry. Zinc-a-2-glycoprotein (ZAG), vita-
min D-binding protein (VDB), serum amyloid-A protein (SAA) and b-2-microglobulin (B2M) had
statistically significant higher concentrations in non-responders compared to responders, while
haptoglobin (Hp) had a lower concentration. ELISAs were used to validate the candidate protein
biomarkers using unfractionated serum from 51 newly diagnosed MM patients (29 responders; 22
non-responders). Using logistic regression, the best possible area under the curve (AUC) was 0.96
using ZAG, VDB and SAA in combination. Leave-one-out-cross-validation (LOOCV) indicated an
overall predictive accuracy of 84% with associated sensitivity and specificity values of 81.8 and
86.2%, respectively. Subsequently, 16 of 22 thalidomide-refractory patients successfully achieved
complete response or very good partial response using second-line treatment suggesting that the
biomarker profile is specific to thalidomide response rather than identifying patients with MM
refractory to all therapies. Using a novel panel of predictive biomarkers, the feasibility of predicting
response to thalidomide-based therapy in previously untreated MM has been demonstrated.
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1 Introduction
Multiple myeloma (MM) is characterized by the proliferation
of malignant plasma cells within a complex inter-dependent
cellular network in the bone marrow (BM). Although MM
remains an incurable blood cancer in the majority of patients,
the development of novel therapies has dramatically
increased response rates and long-term disease control is now
attainable in a significant proportion of patients [1, 2].
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A minority of centers has access to gene expression
profiling and can stratify patients in terms of high- and low-
risk disease, thus potentially individualizing treatment [3].
Molecular and cytogenetic analysis can identify high-risk
groups but these facilities are not available in all centers.
The more widely available International Staging System
(ISS) allows clinicians to identify prognostic groups based
on b-2-microglobulin (B2M) and serum albumin levels
[4, 5]. However, despite major advances in our under-
standing of this complex disease, a relatively standard
remission–induction therapeutic approach is typically used
in patients in similar categories of age and performance
status by the majority of groups [6, 7].
Thalidomide is an oral immunomodulatory [8] drug that
has been shown to be highly active against MM, with
response rates of 30–70% [9]. Recent long-term follow-up
data indicate that patients exposed to thalidomide early in
their treatment history obtain durable benefit [10]. There-
fore, it is likely that thalidomide and its emerging analogues
such as lenalidomide will remain a central component of
anti-MM therapy in the future. Serious side effects observed
with use of thalidomide in MM include thrombo-embolic
disease and peripheral neuropathy. Neuropathy can be
irreversible and may preclude the use of other potentially
neuropathic therapies including bortezomib, thereby
compromising survival.
In this study, we have focused specifically on identifying a
biomarker profile that correlates with response rate to thali-
domide-based regimens in newly diagnosed patients with
MM. We have attempted to devise a proteomic profile using
an accessible platform that will assist clinicians in indivi-
dualizing treatment by identifying patients that will have a
high likelihood of response to thalidomide-based therapy. If
validated in prospective studies, this profile could allow the
physician to choose an alternative therapy in patients
predicted to be resistant to thalidomide-based treatment
thereby avoiding ineffective, potentially costly treatment and
exposure of the patient to unnecessary side effects.
2 Materials and methods
2.1 Patients and sample collection
Serum samples from 51 consecutive newly diagnosed MM
patients who were having initial treatment with thalidomide-
based regimens were analyzed. Samples were obtained at
diagnosis and prior to commencement of therapy. The
samples were collected according to standard phlebotomy
procedures from consented patients. Ethical consent was
granted from the Mater Misericordiae University Hospital,
Dublin, Ireland, ethics committee. Ten milliliters of blood
sample was collected into additive free blood tubes and was
allowed to clot for 30min to 1h at room temperature.
Samples were coded and transported on ice to the laboratory.
The serum was denuded by pipette from the clot and place
into a clean tube. The tubes were centrifuged at 400 relative
centrifugal force (rcf) for 30min at 41C. Serum was aliquoted
in the cryovial tubes, labeled and stored at 801C until time
of analysis. The time from sample procurement to storage at
801C was less than 3h. Each serum sample underwent no
more than three freeze/thaw cycles prior to analysis.
2.2 Removal of high-abundance proteins from
serum samples
Samples were prepared as outlined previously [11]. Briefly,
diluted samples (Buffer A) were centrifuged to remove lipids
and particulates. The Human Multiple Affinity Removal
System (MARS) column was employed to remove 14 of the
most abundant proteins (albumin, IgG, antitrypsin, IgA,
transferrin, haptoglobin (Hp), fibrinogen, a-2-macroglobulin,
a-1-acid glycoprotein, IgM, apolipoprotein AI, apolipoprotein
AII, complement C3 and transthyretin). For each sample, a
low-abundance fraction was collected and concentrated using
5-kDa molecular weight cut-off spin concentrators (Agilent
Technologies). The concentrated depleted serum samples were
collected and immediately transferred and stored at 801C
until further analysis. The depletion protocol was found to be
reproducible as demonstrated byWestern blot analysis using an
anti-albumin antibody, which confirmed the absence of albu-
min from the immunodepleted fraction (results not shown).
2.3 Preparation for 2-D electrophoresis
Proteins from the immunodepleted serum samples were
precipitated prior to labeling using a 2-D Cleanup
Kit (Biorad). The protein pellets were resuspended in ice-
cold DIGE lysis buffer (20mM Tris, 7M Urea, 2M
Thiourea, 4% CHAPS, pH 8.5). Protein quantification
was performed using the Quick Start Bradford Protein
Assay (Biorad) using BSA as a protein standard [11].
2.4 2-D DIGE
Depleted serum samples were labeled with N-hydroxy
succinimidyl ester-derivatives of the cyanine dyes Cy2, Cy3
and Cy5 following a standard protocol [11]. Immobilized
24-cm linear pH gradient (IPG) strips, pH 3–11 NL, were
rehydrated in rehydration buffer (7M urea, 2M thiourea,
4% CHAPS, 0.5% IPG Buffer, 50mM DTT) overnight,
according to the standard guidelines [11, 12]. Isoelectric
focusing (IEF) was performed using an IPGphor apparatus
(GE Healthcare) for a total of 40 kV/h at 201C. Equilibrated
IPG strips were placed on top of 12.5% uniform poly-
acrylamide gels cast between low-fluorescence glass plates.
Strips were sealed on the top of the gels using a sealing
solution (0.5% w/v low-melting-point agarose in running
buffer containing bromphenol blue). Gels were run on the
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Ettan Dalt 12 apparatus (GE Healthcare) using a two-step
protocol, 2.5W/gel for 30min and then 100W in total at
101C until the dye front had run off the bottom of the gels.
2.5 DeCyder analysis
Gels were scanned using the Typhoon 9400 Variable Mode
Imager (GE Healthcare) to generate images at the appropriate
excitation and emission wavelengths from the Cy2-, Cy3- and
Cy5-labeled samples. Subsequently, the gel images were
cropped using ImageQuant software (GE Healthcare) and
imported into Decyder 6.5 software. Decyder 6.5 was used to
compare the immunodepleted serum from responders versus
non-responders to generate lists of differentially expressed
(DE) proteins [11, 13]. The differential in gel analysis (DIA)
module was used to assign spot boundaries and to calculate
parameters such as normalized spot volume. The BVA mode
of DeCyder 6.5 was then used to match all paired image
comparisons from difference in-gel analysis for a comparative
cross gel statistical analysis. At this stage, operator interven-
tion was required for more accurate matching. If the
matching in an area required correction, the current matches
were broken and remade with the appropriate spots [11, 12].
2.6 Spot digestion and identification by mass
spectrometry
Proteins of interest were picked from preparative gels
containing 400mg of protein stained with Colloidal Coomassie
Blue (CBB) stain (Sigma) using the Ettan Spot Picker robot
(GE Healthcare). Tryptic digestions were performed on the
proteins of interest according to standard protocols[11].
Samples were analyzed using a 1-D LC-MS/MS method run
on an Ettan MDLC system (GE Healthcare) in high-through-
put configuration directly connected to a Finnegan LTQ
(Thermo Electron). Samples were initially concentrated and
desalted on RPC trap columns (Zorbax 300SB C18,
0.3mm 5mm, Agilent Technologies). Subsequently,
peptides were separated on a nano-RPC column (Zorbax
300SB C18, 0.075mm 100mm, Agilent Technologies) using
a linear acetonitrile gradient from 0 to 65% ACN (Sigma) over
60min. All buffers used for nano-LC separation contained
0.1% formic acid (Fluka) as the ion pairing reagent [14].
Identification of proteins was carried out using the
Turbo-SEQUEST algorithm in the BioWorks 3.1 software
package (Thermo Electron) and the Swiss-Prot human
database (Swiss Institute of Bioinformatics, Geneva, Swit-
zerland). Peptides were further evaluated using charge state
versus cross-correlation number (XCorr). The following
SEQUEST criteria were selected for high-confidence peptide
identification: XCorr41.5 for singly charged ions,
XCorr42.0 for doubly charged ions, and XCorr42.5 for
triply charged ions, together with a minimum of two
matched peptides for each protein [14, 15].
2.7 ELISA
ELISAs were used to confirm the differential expression of
the five potential biomarkers discovered using 2-D DIGE
analysis. ELISA-based validation was carried out using raw
unfractionated serum samples from the original cohort of
patients. Each sample was analyzed in duplicate using the
following commercially available kits: for the measurement
of human serum amyloid-A protein (SAA) (Invitrogen),
serum Hp (AssayMax), zinc-a-2-glycoprotein (ZAG) (Bio-
Vendor), B2M and vitamin D-binding protein (VDB)
(Immunodiagnostic) kits were used. The ELISA assays were
performed according to each manufacturer’s protocol and
guidelines. The optical density (OD) was measured using a
micro-plate reader (Bio-Tek) and the concentration of each
protein in the serum samples was determined by comparing
the OD of the samples against the respective standard curve
provided by the kit.
2.8 Statistical analysis
DIGE gels were exported for image analysis using the BVA
module of Decyder 6.5 software (GE Healthcare) for
quantitation of protein abundance levels. Following confir-
mation of appropriate spot detection, matching, normal-
ization and spot statistics were reviewed. The normalized
volume of a spot was compared in all the gels between each
group. Spots that were found to be statistically significant by
univariate analysis (t-testr0.01) were selected for further
investigation.
Multivariate logistic regression (LR) and receiver operat-
ing characteristic (ROC) curve analysis were carried out in
the freely available statistical software R (http://www.
r-project.org/). The ROC curves were used to interpret the
utility of LR models for various combinations of the DE
proteins. The probability of correct prediction for a given
model was calculated from the ROC curve by determining
the area under curve (AUC). Proteins and combinations of
proteins returning the largest AUC values are deemed the
most effective for the discrimination of responders from
non-responders [16].
Akaike’s Information Criterion (AIC) was also used as an
additional factor to select the best combination of biomar-
kers. AIC is a commonly used measure to select between
competing statistical models. The AIC is a trade off between
the goodness of fit and model complexity, i.e. the number of
parameters required (in this case proteins).
Sensitivity and specificity values were calculated for the
best combination of biomarkers. Sensitivity is defined as the
percentage of all non-responders who were refractory to a
thalidomide-based treatment regime correctly identified as
having this phenotype based on the panel of protein
biomarkers (the true positive rate). Specificity is defined as
the percentage of all responders who were sensitive to a
thalidomide-based treatment regime correctly identified as
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having this phenotype based on the panel of protein
biomarkers (the true negative rate).
As an additional measure of the potential of these
biomarkers to accurately predict response to thalidomide-
based therapy, a commonly used internal validation tech-
nique known as leave-one-out-cross-validation (LOOCV)
was performed. During the LOOCV procedure, data
from a single observation are removed from the data set
and the remaining samples are then utilized to construct a
LR model. The ‘‘test’’ sample is presented to the trained
model and the performance assessed; LOOCV continues
until each observation is designated as the ‘‘test.’’ The
average performance over the 51 tests is reported as the
LOOCV accuracy.
3 Results
3.1 Sample set
The mean age of the patient group was 68 SD76.95 years
(range 52–81 years); 27 were male and 24 female. Based on
day-100 re-staging investigations and using the Interna-
tional Myeloma Working Group (IMWG) uniform response
criteria for MM [17, 18], 29 responders and 22 non-respon-
ders to thalidomide-based therapy were identified. The
mean age was 66 SD76.80 years (range 52–81 years) for
responders and 70 SD76.69 years (range 57–79 years) for
non-responders. Based on the ISS classification [19], 6
responding patients had stage I, 15 had stage II and 8 had
stage III disease. Two non-responders had stage I, 11 had
stage II and 9 had stage III disease. In the responders group,
24 patients were treated with thalidomide and dexametha-
sone (TD), 3 with thalidomide, cyclophosphamide and
dexamethasone (CTD) and 2 with melphalan, prednisone
and thalidomide (MPT). In the non-responder group, 17
patients received thalidomide and dexamethasone, 4
received thalidomide, cyclophosphamide and dexametha-
sone and 1 patient received melphalan, prednisone and
thalidomide. Median follow-up was 18 months (range 9–27
months). In the responder group, 9 patients achieved
complete response (CR) and 20 achieved very good partial
response (VGPR). Five non-responders had Stable disease
(SD) and the remaining 17 had Progressive disease (PD)
(Table 1). Time to progression (TTP) was defined as the
time from the start of thalidomide-based regimen to the date
of documented progression. Of the 29 responders, 8 even-
tually relapsed with median TTP of 15 months (range 11–18
months). However, median TTP has not been calculated for
this group as 21 patients remain in CR or VGPR.
3.2 Proteomic profiling
Proteins were precipitated from the low-abundance immu-
nodepleted fraction, resuspended in lysis buffer, fluorescently
labeled and analyzed by 2-D DIGE using an internal standard
design. This analysis was performed on 39 newly diagnosed
MM patients (22 responders; 17 non-responders). Spot maps
were generated and maps were aligned with a master spot
map; relative abundance values were generated for each of 886
protein spots that were common to more than 90% of gels.
Based on 2-D DIGE analysis, protein spots with a fold change
of Z1.25 in abundance level and a t-test of r0.01 were
selected. Using these criteria, five individual DE proteins spots
were detected. Four proteins were increased in abundance
level, and one was decreased in abundance level in thalido-
mide non-responders compared to responders. Figure 1
shows DeCyder analysis for B2M and Hp, indicating that
these proteins were increased and decreased in abundance
levels, respectively, between non-responders and responders
to thalidomide-based therapy. Gel images and 3-D protein
spot views for Hp and B2M are also displayed, demonstrating
a clear difference in the abundance levels (Fig. 1).
3.3 Protein identification
Subsequently, these proteins of interest were identified by
LC-MS/MS using an ion trap LTQ mass spectrometer and
searched against the SWISS-PROT database using
SEQUEST [20–22]. The serum Hp fragment, which was the
only protein found to have a lower abundance level in non-
responders compared to responders, was identified by LC-
MS/MS resulting in nine matched peptides corresponding
to a sequence coverage of 11.58% (Table 2). Proteins found
to have higher abundance levels between non-responders
and responders to thalidomide-based therapy were ZAG,
VDB, SAA and B2M. These proteins were identified by LC-
MS/MS resulting in 10, 20, 4, and 3 matched peptides,
respectively, corresponding to a 37.63, 53.59, 48.36 and
35.29% sequence coverage, respectively (Table 2).
3.4 DeCyder ratios, ELISA data and ROC curve
analysis
In this study, ELISA-based assays were used to measure the
levels of the five candidate marker proteins in serum from
thalidomide responders and non-responders (Supporting
Information Table S1). The ELISA-based assays were
performed on a larger cohort compared to the 2-D DIGE
analysis, consisting of 51 consecutive MM patients (29
responders; 22 non-responders). The five DE protein
concentrations were measured in duplicate for each patient.
The box plots show the data for responders and non-
responders (Fig. 2). The horizontal line within the boxes
represents the median. The upper and lower box edges are
the 1st and 3rd quartiles. The whiskers reach the nearest
value within 1.5 times the inter-quartile range. The points
outside the whiskers are considered outliers; however, no
outlier value was removed from our analysis.
1394 R. Rajpal et al. Proteomics 2011, 11, 1391–1402
& 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
Table 1. Clinical details for the patients included in this study
Patients’ age Patients sex Clinical ‘‘ISS’’ stage Day-100 IMWG re-staging Response to thalidomide Follow-up (months)
Responders
73 F III VGPR R 17
66 M II CR R 16
58 F III CR R 16
67 M II VGPR R 12
59 M III VGPR R 18
67 M III CR R 16
72 M III CR R 13
60 M II CR R 19
71 F II VGPR R 13
69 M I VGPR R 12
61 F II CR R 19
74 F I VGPR R 13
70 F II VGPR R 14
61 F I VGPR R 12
77 M II VGPR R 14
63 M I CR R 14
58 F I VGPR R 15
59 F I VGPR R 14
64 M II CR R 12
63 F II VGPR R 21
65 M II VGPR R 8
70 M III VGPR R 7
66 F II CR R 8
80 M II VGPR R 7
66 F II VGPR R 10
81 F III VGPR R 6
52 M III VGPR R 11
64 M II VGPR R 6
68 F II VGPR R 6
Non-responders
72 F II PD NR 16
74 M III PD NR 12
71 M III PD NR 19
65 M II PD NR 11
70 M III PD NR 17
63 F III PD NR 14
72 M III PD NR 16
63 M II SD NR 11
78 M II PD NR 10
79 F II PD NR 15
57 F III PD NR 10
77 M III PD NR 12
78 F II PD NR 15
64 F II PD NR 21
65 F I SD NR 20
73 F III PD NR 18
78 M II SD NR 11
61 F II SD NR 12
76 F III PD NR 9
77 M II PD NR 11
62 M I PD NR 8
69 M II SD NR 6
Clinical details include age, sex, ISS (International Staging System), day 100 restaging results based on IMWG uniform response criteria
for MM. The last column shows duration of follow-up in months. Abbreviations: CR: complete response; VGPR: very good partial
response; SD: stable disease; PD: progressive disease; IMWG: International Myeloma Working Group; R: responders to thalidomide-based
therapy; NR: non-responders to thalidomide-based therapy; M: male; F: female.
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In clinical practice, it is rare that a chosen cut off point
for a single analyte will achieve perfect discrimination
between various groups of patients, and one has to select the
best compromise between sensitivity and specificity by
comparing the diagnostic performance of different tests or
diagnostic criteria available. In this study, we assessed the
suitability of a panel of proteins for potential clinical appli-
cation using LR ROC curves and report the AUC of each
test. ROC curves allow systematic analysis of the diagnostic
performance of a test, a comparison of the performance of
different tests, and the AUC provides a summary measure
of the utility of the model [23, 24]. In our study, we deter-
mined the potential impact of the use of ZAG, SAA, VDB,
B2M and Hp as single or combination biomarkers for
distinguishing between responders and non-responders to
thalidomide-based therapy in MM patients. The ELISA
values for each of these five proteins were used to develop
multivariate LR models and the subsequent ROC curves
generated (Fig. 3) and the AUC determined.
2-D DIGE and ELISA analysis showed that ZAG had a
1.48- (p5 0.0000022) and a 1.27-fold (p5 0.00398) increase in
abundance levels in non-responders compared to responders,
respectively (Table 2), as determined by univariate analysis.
The ROC curve generated from the ELISA data for ZAG
yielded an AUC of 0.76 as an individual protein (Fig. 3).
Results for SAA showed a 3.01-fold (p5 0.006) increase in
abundance levels for non-responders compared to responders
using 2-D DIGE protein profiling analysis. This result
correlated strongly with data from the ELISA analysis, indi-
cating a 3.80-fold (p5 0.00016) increase in SAA abundance
levels in non-responders compared to responders (Table 2).
ROC curves calculated from this ELISA data showed an AUC
of 0.82 (Fig. 3), indicating excellent discriminatory power for
this single protein. SAA is a sensitive marker of inflamma-
tion [25, 26]. In the 22 non-responder patients studied in this
project, none had evidence of infection or fever at the time of
sampling; out of 29 responder patients, 1 had an infection
resulting in mild fever. Therefore, the SAA elevation in the
non-responder patients appeared to be unrelated to infection
or inflammation.
Hp is normally removed by the immunodepletion
column; however, using 2-D DIGE analysis followed by
Figure 1. Statistical analysis of Hp and B2M respectively, using DeCyder BVA software. (A) and (B) display that these proteins were found
to be 3.01-fold decreased and 1.96-fold increased, respectively, in the immunodepleted serum from non-responders compared to
responders. (C) and (D) also show gel images and 3-D views for Hp and B2M, respectively, showing a clear change in expression levels.
B2M: b-2-microglobulin, Hp: haptoglobin.
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LC-MS/MS, an 10-kDa Hp fragment was identified
[27, 28]. We suggest that this Hp fragment was not removed
due to its size and non-interaction with the specific Hp
antibody in the affinity column, and hence it was detected in
the 2-D DIGE analysis. In the protein profiling analysis, the
Hp fragment was found to be 3.01-fold (p5 0.0015)
decreased in serum from non-responders compared to
responders. As intact Hp was removed from this analysis
because of the immunodepletion column, it was decided to
investigate this protein using an ELISA-based assay
approach. Data from the ELISA analysis for intact Hp
showed a 1.73-fold (p5 0.03241) decrease in abundance
levels in non-responders compared to responder. ROC
curves were generated from the ELISA data, which showed
an AUC of 0.64 (Fig. 3). The decrease in abundance of the
Hp fragment seen in thalidomide non-responders compared
to responders using 2-D DIGE analysis displayed a similar
trend to that of the intact Hp detected by ELISA analysis in
the unfractionated serum samples (Table 2).
2-D DIGE data and ELISA results showed a 1.96-
(p5 0.0015) and 2.00-fold (p5 0.00118) increase, respec-
tively, in the abundance level of B2M from non-responders
compared to responders. The ROC curve generated from
this data yielded an AUC of 0.87, indicating excellent
discriminatory power for this protein (Fig. 3). The VDB
protein level from 2-D DIGE analysis and ELISA data
showed a 1.31 (p5 0.00044) and 1.28 (p5 0.02045) fold
increase in abundance levels, respectively, from non-
responders compared to responders (Table 2). ROC curves
were generated from the ELISA data and showed an AUC of
0.70 (Fig. 3).
3.5 Logistic regression with multiple proteins
Initially, LR was used to develop predictive models for each
individual DE protein (Fig. 3). The best predictive single
proteins from the LR model were B2M and SAA, with AUC
values of 0.87 and 0.82, respectively. The remaining single
protein model had AUC values less than 0.8, indicating
poorer predictive ability (Fig. 3). The predictive capability of
models developed based upon combinations of proteins was
also assessed. LR models were constructed and ROC
analysis carried out on all possible permutations of the DE
proteins. The three most successful combinations of
biomarkers from this analysis for predicting response to
thalidomide-based therapy were found to be Hp, SAA, VDB
(AUC5 0.96, LOOCV5 84.31, AIC5 35.26), ZAG, B2M,
SAA, VDB (AUC5 0.96, LOOCV5 84.31, AIC5 37.02) and
B2M, SAA, VDB (AUC5 0.94, LOOCV5 84.31, AIC5
36.59). The combination of Hp, SAA, VDB was found to be
the most successful based on the values from the AUC,
LOOCV and AIC analyses as shown (Fig. 4). The sensitivity
and specificity of this model was 81.81 and 86.20%,
respectively.
In this analysis, CRP level at diagnosis was also assessed
but did not improve the predictive capability of this model.
CRP was found to have a mean of 10.4717.7 mg/mL in
responders compared to 12.1723.6 mg/mL in non-respon-
ders (p5 0.770749339). CRP was found to have an AUC of
0.4, indicating no discriminatory power for predicting
response to thalidomide-based therapy.
No correlation between clinical parameters such as age
and gender and response to thalidomide was found. Also,
individual clinical parameters were combined with the
model to determine if classification accuracy could be
improved. However, no clinical parameter improved classi-
fication accuracy for thalidomide response.
3.6 Calculation of non-response probability
The equation shown here, allows for the calculation of the
probability (p) of a patient being a non-responder based on
the serum concentrations of ZAG, Hp and VDB as deter-
mined using ELISAs. Each protein concentration in mg/mL
is first multiplied by the regression coefficient (derived
from the fitted model) as per the equation below. If the
resulting value of p is below 0.5, response to thalidomide is
predicted and if the value is above 0.5, non-response to
thalidomide is predicted. As additional patient data is
accumulated from future randomized clinical trials, the
Table 2. Protein identities obtained by LC-MS/MS analysis
Protein name MW
(Da)
Matched
peptides
%
Coverage
XC-
score
DeCyder
ratio
DeCyder
p-value
ELISA
ratio
ELISA
p-value
Vitamin D-binding protein (VDB) 52930 20 53.59 210.4 1.31 0.00044 1.28 0.02045
Haptoglobin fragment (Hp) 45177 9 11.58 76.3 3.01 0.0017 1.73 0.03241
Zinc-a-2-glycoprotein (ZAG) 33851 10 37.63 170.3 1.48 0.0000022 1.27 0.00398
b-2-microglobulin (B2M) 13706 3 35.29 46.3 1.96 0.0015 2 0.00118
Serum Amyloid A Protein (SAA) 13524 4 48.36 80.3 3.01 0.006 3.8 0.00016
Listed are the protein identities obtained by LC-MS/MS analysis, molecular weight (MW), number of matched peptides related to the
protein, percentage coverage of the protein sequence identified, XC-Score (Sequest score ), DeCyder ratio with associated p-value
(immunodepleted serum) and ELISA ratio (NR/R) with associated p-value (unfractionated serum). The DeCyder ratio for Hp is the 10 kDa
fragment identified in the 2-D DIGE analysis while the ELISA ratio is based on the intact form of this protein.
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values of the regression coefficients may be altered
(Supporting Information Table S2).
p ¼ 1
11eðð0:001037HpÞ1ð0:017653SAAÞ1ð0:013311VDBÞ8:603880Þ
4 Discussion
Clinical trials of thalidomide have shown variable results
[29, 30]. We believe that part of the reason for this is the
application of a standardized approach to therapy for a
heterogeneous group of patients. There is a significant risk
of major acute adverse events (National Cancer Institute
Common Toxicity Criteria Grade III–IV) including throm-
bosis (20%), infection (12%) and irreversible neuropathy
(8%) associated with thalidomide-based therapy [31, 32],
which can be both cumulative as well as dose related [33].
Furthermore, the development of severe neuropathy can
preclude the future use of other neurotoxic agents including
bortezomib. Therefore, it is clearly desirable to develop
means to predict responders to thalidomide in order to
maximize the benefit to risk ratio in MM patients.
The mechanism of action of thalidomide and its analo-
gues is mediated through modulation of the cells of the
microenvironment with anti-inflammatory and immuno-
modulatory effects [8, 34]. These include downregulation of
stromal cell adhesion molecules, inhibition of secretion of
angiogenic and survival growth factors, pleiotropic immuno-
modulatory effects including inhibition of tumor necrosis
factor-alpha (TNF-a) secretion, stimulation of IL2 and
interferon-gamma (IFNg). Cellular targets include lympho-
cytes, monocytes and NK cells [35]. In patients with an
activated immune system, thalidomide inhibits tumor
necrosis factor-a secretion from monocytes [36] and down-
regulates secretion of stimulatory cytokines including IL1,
IL6, IL12 and GMCSF [37]. Conversely, thalidomide has
been shown to co-stimulate CD41T cells by CD28 phos-
phorylation. In vitro, immunomodulatory effects of thali-
Figure 2. Displayed are the concentrations for
the five differentially expressed proteins,
obtained in duplicate for each patient using
ELISAs. The box plots show the data for
responder and non-responder patients. The
horizontal lines within the boxes represent
the median. The upper and lower box edges
are the 1st and 3rd quartiles. The whiskers
reach the nearest value within 1.5 times the
inter quartile range. The points outside the
whiskers are considered outliers. (A) B2M: b-
2-microglobulin; (B) VDB: vitamin D-binding
protein; (C) ZAG: zinc-a-2-glycoprotein; (D)
Hp: haptoglobin; (E) SAA: serum amyloid-A
protein.
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domide and its analogues therefore vary depending on the
level of activation of the patient’s immune system. Using
2-D DIGE and MS technologies, we have previously
demonstrated novel biomarkers for the early detection of
squamous carcinoma of lung [11] and proteins associated
with tumor progression in squamous cell carcinoma of the
head and neck region [14]. We have adopted a similar
scientific approach to the analysis of serum from newly
diagnosed MM patients. Interestingly, ZAG, VDB, SAA,
B2M and Hp were the five individual proteins with statis-
tically different concentrations between responders and
non-responders. A combination of protein biomarkers
consisting of serum proteins ZAG, SAA and VDB yielded an
AUC of 0.96, indicating an outstanding predictive capability.
B2M is an 11-kD protein associated with the outer
membrane of many cells including lymphocytes. It is the
small subunit of the MHC class I molecule and is present in
small amounts in serum, CSF and urine of normal people. In
patients with MM, B2M has been confirmed as a highly
significant prognostic factor in combination with albumin as
part of the ISS. ZAG is an adipokine with structural organi-
zation and folding similar to MHC class I antigen-presenting
molecules and therefore may have a role in the immune
response [38]. SAA is an apolipoprotein synthesized in
response to inflammatory cytokines released by activated
monocytes as well as macrophages, and also has a role in
fibrosis [39, 40]. Its persistently high concentration is also a
prerequisite for the development of AA Amyloidosis [41].
VDB protein is a glycoprotein that functions as the main
carrier for vitamin D and its hydroxylated metabolites in the
plasma. It is also a precursor for the principal macrophage-
activating factor (MAF) [42, 43]. VDB is present on the surface
of several cell types including T and B lymphocytes. Hp is a
glycoprotein mainly secreted by hepatocytes in response to a
variety of stimuli mainly as an acute phase protein and has
been shown to have angiogenic effects [44–46].
In vitro, it has been shown that thalidomide analogues
can have variable effects depending on the immunological
status of the patient [35, 47]. Interestingly, four of the five
proteins with increased concentration in non-responders to
thalidomide are acute phase reactants. However, Hp and
CRP, two significant acute phase proteins, were not found to
be of higher abundance in the non-responder group so it is
unclear if the response is related to acute phase or immune
response.
Figure 3. Logistic regression analysis used to develop a predic-
tive model for each individual differentially expressed protein.
The performance of the models was assessed using ROC curves
(A), and the AUC for each individual protein are shown (B). The
best predictive ability for logistic regression model for single
proteins was for B2M and SAA, with AUC values of 0.87 and
0.82, respectively. ZAG: zinc-a-2-glycoprotein; VDB: vitamin D-
binding protein; SAA: serum amyloid-A protein; B2M: b-2-
microglobulin; Hp: haptoglobin.
Figure 4. ROC curve analysis using a combination of Hp, SAA
and VDB. The best possible AUC was found with combined Hp,
SAA and VDB, which yielded an AUC of 0.96 indicating excellent
discriminatory power. Hp: haptoglobin; SAA: serum amyloid-A
protein; VDB: vitamin D-binding protein.
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Thalidomide has potent anti-angiogenic effects mediated
by AKT signaling and secretion of angiogenic cytokines [48].
The observation that Hp, a pro-angiogenic protein, has a
higher concentration in responders to thalidomide supports
the idea that inhibition of angiogenesis is an important part
of disease response to thalidomide.
We considered the possibility that the non-responders
were simply patients with disease that would be refractory to
all therapies. Of 22 non-responders to thalidomide, 16
successfully achieved CR/VGPR using other therapies
including bortezomib and lenalidomide (Supporting Infor-
mation Table S3). This suggests that the biomarker profile is
predictive of thalidomide response rather than that the non-
responders were simply patients with MM refractory to all
therapies (Supporting Information Table S3). Furthermore,
these data suggest that, had the non-responsive patients
received an alternative to thalidomide as induction
therapy, a significant response could have been obtained.
The ISS, based on serum B2M and albumin levels, is a
predictor of overall survival in MM patients [17, 49]. The
endpoint in our study was response to thalidomide in
contrast to survival (as applied to the ISS) and we found no
correlation between ISS values and response rate to thali-
domide. Moreover, incorporation of albumin, B2M and CRP
into the Hp/VDB/SAA panel did not improve predictive
ability (data not shown).
In conclusion, accurate prediction of sensitivity to thali-
domide will help progress toward the goal of personalized
medicine in MM patients. We have identified a predictive
biomarker panel that has the potential to allow thalidomide-
based therapy to be directed to patients with sensitive
disease resulting in higher response rates. Avoidance of
thalidomide use in patients with unresponsive disease will
decrease unnecessary potential side effects including
thrombo-embolic disease and irreversible peripheral neuro-
pathy. Better response rates and avoidance of therapy and
disease-related complications will increase patient quality of
life, reduce cost to health care providers and may impact on
survival. However, 2-D DIGE analysis is expensive, labor
intensive and requires complex equipment and advanced
analytical skills, limiting its applicability to only a minority
of clinical centers. ELISA tests are inexpensive, robust,
sensitive, specific and widely used in hematopathology
laboratories attached to clinical units. For this reason, we
validated the results from the 2-D DIGE using commercially
available ELISA kits. Validation of this proteomic profile
using ELISA in large-scale prospective trials of patients
receiving thalidomide in the setting of induction, relapse
and post-transplant maintenance is required to further
define its clinical utility and to expand this paradigm to
other agents.
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